Stroke · 2025
ARISE II Consensus on the Management of Intracranial Atherosclerotic Disease.
СтатьяОбзорConsensus StatementНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tjoumakaris Stavropoula I, Roy Joanna M, Amin-Hanjani Sepideh, Charbel Fady T, Dabus Guilherme, Fisher Marc, Gounis Matthew, Hoh Brian L, Liebeskind David S, Linfante Italo, Samaniego Edgar A, Toth Gabor, Zaidat Osama O, Bhogal Pervinder, Arthur Adam, Wakhloo Ajay K, ARISE II Academic Industry Roundtable
Аннотация
Intracranial atherosclerotic disease (ICAD) is one of the leading causes of ischemic stroke worldwide. Despite advances in its diagnosis and management, there is no clear consensus on best practices to manage ICAD. This report summarizes the ARISE II (Roundtable Discussion With Industry and Stroke Experts) consensus in treating ICAD. The consensus underscored the importance of lifestyle modification and medical management in patients with ICAD. Patients who fail medical management are candidates for endovascular treatment. Open surgery is not recommended in patients who lack demonstrated hemodynamic insufficiency. The consensus also identified gaps in knowledge about the optimal duration of antithrombotics, the effect of the CYP2C19 genotype on medical management, the need for newer devices, and the standardization of antithrombotic protocols before stenting in an acute setting. Optical coherence tomography requires additional clinical data before defining its role in the diagnosis of ICAD.